Implementation of Long-Acting Drugs for Treatment and Prevention of HIV

Last Modified: Apr 8, 2024 @ 3:10 PM

Program Description

This half-day virtual course will include an overview of the challenges in the implementation of long-acting drugs for the treatment and prevention of HIV and explore the latest research on the use of long-acting drugs for the treatment and prevention of HIV. Information will be presented through a mix of didactic lectures, clinically relevant cases, and expert panel discussions developed and led by an expert faculty of HIV/AIDS clinicians and researchers.

Assessment of Needs

Rapid advances in HIV disease management information require the ongoing attention of practitioners involved in direct patient care. The overall objective of the course is to address the current knowledge and practice gaps in the use of long-acting drugs for the treatment and prevention of HIV, including the barriers to their effective implementation. This course will review the current state and understanding of long-acting drugs for the treatment and prevention of HIV, the evidence supporting their use, and the challenges and implications involved in their implementation. Additionally, this course will also address the resistance implications of treatment and prevention failure and identify implementation-related operational challenges.

Learning Objectives

After participating in the activity, learners will be able to:

• Describe the available data supporting the use of long-acting drugs for the treatment and prevention of HIV, including their efficacy and safety
• Assess the implications of treatment and prevention failure in long-acting drug regimens, particularly the development and impact of drug resistance
• Identify operational challenges in delivering and implementing long-acting drugs for the treatment and prevention of HIV, including management, healthcare practitioner training, patient adherence, healthcare infrastructure, and payer landscape

Topics

• Data supporting long-acting drugs for treatment of HIV
• Data supporting long-acting drugs for prevention of HIV
• Challenging cases in implementing long-acting drugs for treatment and prevention of HIV (panel discussion)
• Implication of resistance to long-acting treatment and prevention failure
• Operational challenges for treatment and prevention

Conflicts of Interest

In the interest of maintaining the independence of its continuing medical education (CME) activities, the International Antiviral Society–USA (IAS–USA) requires all persons with control of educational content (eg, faculty, Scientific Leadership Board, Governance Board, and program planner) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved and mitigated prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in IAS–USA CME activities.  

The Accreditation Council for Continuing Medical Education (ACCME) defines ineligible companies as “those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.” 

IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies for the presenters and planners/reviewers will be available in the esyllabus and in the slides prior to the presentation of educational content. 

Registration

Who Should Attend

This course is designed for physicians who are actively involved in the medical care of people with HIV infection and:

• Have a solid, working knowledge of HIV disease management
• Provide comprehensive or specialty care for patients with HIV infection
• Are currently active in HIV research

This activity is also relevant to nurse practitioners, registered nurses, physician assistants, registered pharmacists, and other health professionals.

Representatives and employees of commercial companies (eg, pharmaceutical, diagnostic, medical products, advertising, insurance, investment, and communications firms) must contact the IAS–USA regarding registration procedures.

Cancellation Policy

Cancellation requests must be made 7 or more days before the date of an activity. All refunds will be processed minus a $15.00 processing charge. Regrettably, any cancellation requests received within a week before the course will not be eligible for the partial refund.

Continuing Education Credits

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 4.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Points